Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib
Single Arm Phase 2 Trial of Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib (TOP 1901)
Sponsor: Duke University
Terminated
low accrual
Other terminated trials from Duke University
Other Non Small Cell Lung Cancer trials with similar outcome
This PHASE2 trial investigates Non Small Cell Lung Cancer and is currently terminated or withdrawn. Duke University leads this study, which shows 15 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Terminated PHASE2
-
Jul 2023 — Jan 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
May 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 10 earlier versions
-
Jun 2022 — May 2023 [monthly]
Active Not Recruiting PHASE2
Status: Suspended → Active Not Recruiting
-
Jan 2022 — Jun 2022 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Mar 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2020 — Apr 2020 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2019 — Feb 2020 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Duke University
For direct contact, visit the study record on ClinicalTrials.gov .